Though the incidence of complications and adverse events with dermatological fillers is inherently low, practitioners should be well versed in both prevention of filler complications and the treatment algorithms for addressing "granulomas," nodules, infection, and vascular compromise. Appropriate preventative measures, coupled with timely and effective treatment, are critically important for patient safety and satisfaction. In addition to the preventive measures and treatment algorithms outlined here, the authors emphasize that the broad classification and treatment of nodules as "granulomas" is likely to lead to ineffective treatment, or worse, unnecessary exposure to incorrect treatment. In practice, nodules are classified and treated based on clinical manifestation (eg, late vs early or noninflammatory vs inflammatory) rather than on histology. Indeed, classification of a nodule as a granuloma requires a histological examination, rarely available (or necessary) in clinical practice to guide treatment. Thus, the apparent inflammatory nature of the nodule and the time of onset should drive treatment approach. The treatment algorithms presented here are based on these clinically meaningful parameters.
overcorrection, palpable nodules, granulomas, infection, open wounds, soreness at the injection site, allergic reaction, or necrosis. 4 Other rare side effects reported to the FDA have included migration and movement, permanent hard nodules, injury to blood supply, and vision abnormalities. 4 In 2008, the FDA published a study characterizing the incidence of adverse events related to dermal filler medical devices that included international data derived from the Manufacturer and User Facility Device Experience (MAUDE) database. 5 Between January 1, 2003 and September 20, 2008 , 930 adverse events were reported to the FDA, reflecting the low risk for adverse events observed in clinical practice. The most common adverse events according to this report are shown in order of decreasing frequency in Figure 4 of the report, with the top three events of swelling, inflammation, and erythema. Due to the limitations of the reporting in the database, the injection practices of the administering clinician are unclear; however, in the experience of the authors, the low incidence of these events in their own clinical practices and in the practices of their peers suggests it is likely that these incidences are overestimates, and that many of these adverse events are tied to inexperience with or misuse of the injectable agent.
Individuals may experience adverse events due to the composition of the filler product-independent of procedure, or as a result of technical errors. 6 Adverse events may be categorized as related to the product, injection, or technique. Each of these categories is addressed separately below, followed by a series of treatment algorithms to address adverse events.
Product-Related
Product-related sequelae are influenced by the physiochemical properties of the filler, and are shaped by the response of an individual's body to the product. Fillers may be classified as temporary or permanent. Temporary fillers are biodegradable and metabolized or otherwise degraded by the body. The longevity of their aesthetic-enhancing effects is dependent on the type and amount of filler, treatment location, and injection technique utilized. 7 FDA-approved temporary fillers include collagen, HA, and calcium hydroxylapatite (CaHA). Poly-L-lactic acid (PLLA) is not technically a filler, as it relies exclusively on its biostimulatory properties to incite colaganogenesis; however, the results of this volumizing agent are not permanent, allowing it to be classified as a temporary filler. 4 Polymethylmethacrylate (PMMA) microspheres are the only permanent, nonbiodegradable, biocompatible, synthetic filler approved by the FDA. 4 
Permanence-Related Safety Considerations
Collagen was first approved by the FDA in 1981 for correction of contour deficiencies in the dermis. 4 Porcine, bovine, and human-based collagen products have existed in the market. The first HA filler, Restylane (Galderma Laboratories, Fort Worth, TX), was approved by the FDA in 2003. In addition to the Restylane family of products (Restylane, Restylane-L, Perlane, Perlane-L, Restylane Silk, Restylane Defyne, and Restylane Refyne), FDA-approved HA fillers include Juvederm (Allergan, Dublin, Republic of Ireland; Juvederm Ultra XC, Juvederm Ultra Plus XC, Juvederm Voluma XC, Juvederm Volbella XC, Juvederm Vollure XC) and Belotero (Merz Aesthetics, Raleigh, NC). 4, 8 HA fillers are by far the most popular filler, accounting for 2.4 million of the 2.7 million soft tissue filler procedures performed in 2016. 3 Regardless of filler composition, fillers are regulated by the FDA as devices (ie, implants), rather than as drugs or medicines, making the regulations governing product safety and use different from those for medications.
HA is a polysaccharide universally found in mammalian skin and connective tissue. The HA gel matrix material acts as a scaffold for the binding of structural proteins like collagen and elastin. From a safety perspective, HA fillers provide several advantages over collagen fillers: (1) they have improved lifting capacity (a smaller volume is required to achieve lifting in the midface), improved longevity, and no requirement for an allergy skin test 9 ; and (2) the actions of HA fillers can be reversed with hyaluronidase. An additional safety advantage of HAs is that they are naturally degraded by the body over time.
The FDA approved the PLLA filler Sculptra (Galderma Laboratories, Fort Worth, TX) in 2004 for facial lipoatrophy related to human immunodeficiency virus (HIV). PLLA is not, strictly speaking, a filler, as it relies exclusively on its ability to stimulate collagen deposition by fibroblasts, a process that necessitates a period of weeks before results can be appreciated. 9 Sculptra was widely used off label for aesthetic treatments before it was granted approval to treat shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in 2009. 9 Its popularity, however, has been limited by its lack of reversibility and dependence on multiple treatments for effectiveness. 9 Importantly, the comparatively high level of adverse events in early clinical trials has been significantly reduced by adjustments to treatment protocols and handling recommendations. 10 The FDA also approved CaHA, marketed as Radiesse, in 2006 for HIV-related facial lipoatrophy and injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds. Calcium hydroxylapatite is a mineral-like compound found in human bones and teeth. 11 The agent itself behaves as a liquid implant, providing immediate volume and support while stimulating collagen by initiation a subclinical inflammatory response and subsequent collagen formation in a fashion that is similar to PLLA. 12 Because Radiesse can be injected in the supraperiosteal plane, which has less resident vasculature than more superficial planes, effective composite volumization can be achieved safely. 13 The effects of Radiesse can last a year or more and are not immediately reversible. Radiesse should not be used in the lip or in concentric muscle. 9 The PMMA filler Bellafill (previously Artefill; Suneva Medical, Inc., Santa Barbara, CA) was approved by the FDA in 2006 for use in facial tissue around the mouth. Bellafill is a nonresorbable filler made from PMMA microspheres suspended in a collagen matrix that contains lidocaine. 14 Bellafill was more recently approved in 2015 for the treatment of acne scars. Treatment with this filler requires bovine collagen allergy testing to aid in minimizing the risk of hypersensitivity reactions. 15 Though longevity is desirable in a filler, permanence restricts the ability to adapt to the changing needs of the patient that are known to accompany further aging. 16 
Hypersensitivity
The incidence of hypersensitivity-related adverse events varies with the material of the filler. For example, the incidence of preexisting hypersensitivity to bovine collagen is between 2% and 4%. [17] [18] [19] In contrast, hypersensitivity reactions to HA fillers are less than 0.15%. 20, 21 Because of the collagen carrier, the risk for hypersensitivity and allergic reaction to PMMA is slightly higher than that of HA fillers at 0.2%. 15 This rate of allergic reaction is far lower than that of bovine collagen because the manufacturing process includes removal of antigenic atelo peptides present at the ends of native collagen polymers responsible for initiating the immune reaction responsible for hypersensitivity. Long-term adverse events associated with Bellafill may include lumps under the skin and late foreign-body granulomas. 22 CaHA does not require hypersensitivity testing because it consists of the inert components found in bone.
Injection-Related
The rapid adoption of dermal filler injections, coupled with their relative accessibility, has moved treatment with injectable beyond traditional physician-based settings. Though the incidence of adverse events with fillers is indeed inherently low, the experience and training of the injector is critical for obtaining treatment with minimal risk. The FDA recommends that individuals consider dermal filler injections a medical procedure, not a cosmetic treatment, and seek out a dermatology or plastic surgery specialist specifically trained to perform dermal filler injection procedures. 4 The experience and credentials of the injector will not only minimize the incidence of adverse events, but are directly related to the ability of the injector to appropriately and quickly respond to serious events.
Injection technique should be based upon product type, amount, and injection location. 23, 24 Understanding the anatomical areas to which individual fillers are best suited is central to the prevention of adverse events: in each instance, the ability of the filler to provide the desired results must be weighed against the risk of adverse events. Fillers must be injected at the appropriate depth, as superficial injections may result in redness, blanching, or granules. 25 In the case of Radiesse, many of these adverse events may be avoided, as composite lifting can be achieved by injecting the material directly over bone, a plane generally absent of nerves and vasculature. Of course, a detailed knowledge of anatomy is a prerequisite for any injector, and a grasp of those features that should never be approached with a needle or cannula is required. For example, even within the supraperiosteal plane, the path of foramen should be avoided. Further, patterns of facial vascular arborization may vary, and a detailed knowledge of these patterns is critical. Additionally, the filler must be injected at the appropriate location as blockage of a subdermal artery can lead to skin necrosis. 25 Blindness is a rare complication, but can result if the filler occludes the ophthalmic, central retinal, or branch retinal arteries. 26 Occlusion can occur even following injection into distant sites, most commonly the glabella, nasal region, nasolabial fold, and forehead. 25, 27 Blindness from vascular compromise is nearly always irreversible, and there have been no reported cases of recovery after central retinal artery embolization once blindness has occurred, making prevention of paramount importance. Experimental occlusion of the central retinal artery in rhesus monkeys showed time limitations surrounding restoration of blood flow of 97 minutes, 28 indicating that the window in which restoration of blood flow may have a positive impact is limited.
Injection technique is critically important to the success of filler procedures. The most common injection techniques include linear threading, serial puncture, fanning, and cross-hatching. 24, 29 In a prospective, blinded, controlled study of 283 patients who randomly received either Restylane or Perlane, fan-like needle use, rapid injection, rapid flow rates, and higher volumes were associated with an increased incidence of adverse events. 30 Multiple punctures and deep subcutaneous injection did not appear to be associated with an increase in the frequency of adverse events. 30 To minimize compromise of vasculature, small syringes, small volumes, or blunt cannulae may be used. 24 Cannula use can also minimize the number of required injections, improving patient comfort and reducing the risk of infection; for this reason, cannulae are especially well suited for traversing the subdermal fasciae in the hand for filler-based rejuvenation.
Technique-Related
Avoidance of adverse events begins with patient selection: patients should be properly counseled and properly assessed. 24 If necessary, allergy testing should be performed prior to the procedure. Any procedure involving injection of a foreign substance into the body carries a risk of infection; Staphylococcus aureus can lead to the presence of erythematous and/or fluctuant nodules. 6 While most infections present within two weeks of injection, new lesions that occur longer than two weeks after the procedure may indicate an atypical infection, often attributable to inadequate sterilization procedures. 6 
Treatment Algorithms
Condition-specific treatment algorithms must be followed to address complications. Although the term "nodule" and "granuloma" are sometimes used interchangeably, they are distinct entities. A nodule is a visible or palpable bump under the skin that may result from excess filler, placement into the incorrect plane (a superficial or intramuscular injection), an early foreign body reaction, or infection, 1 whereas granulomas are formed as a result of the body's protective mechanism to isolate foreign bodies, preventing migration and depressing efforts to reject the implant. 31 Over the years, language applied to nodules, granulomas, and infection has been fluid, a counterproductive pattern given that distinct biochemical pathways are at play in each situation. Further, treatments for different types of nodules are often in opposition, for example, anti-inflammatory treatment vs administration of antibiotics. The technical differentiation of nodules from granulomas relies upon histology of biopsies: because nodules are not biopsied in clinical practice, the treatment algorithms here are based upon clinical presentation alone. Because "granuloma" is a histological diagnosis, the authors utilize a nomenclature for treatment algorithms that classify nodules either as noninflammatory or inflammatory and further divide these two classifications into early or late onset. The inflammatory nature of the nodule and the time of onset should drive treatment approach and inform assessment for potential infection.
Early Onset Nodules

Overfill or Collection of Material
If the injector overfills a particular area, the injector may first massage the area to disperse the product. If the overfill persists, the skin may be nicked and excess filler expressed. This approach is best suited to situations where the filler is placed superficially. If the filler is placed deep, or there is excess remaining or diffuse product after primary treatment, hyaluronidase should be injected to disperse the material. Like the other complications listed in this article, it is important to focus efforts on prevention. Slow injection by an experienced clinician is preferred.
Noninflammatory Early Onset Nodules
Noninflammatory nodules consist of fluid droplets or microparticles surrounded by a normal foreign body reaction. Histologically, the beads or particles within the nodules stick together as they do in the injected filler, and are not surrounded by macrophages, as seen in late inflammatory reactions (foreign body granulomas). Noninflammatory nodules typically result from technical errors, such as excess filler in an area or placement of inappropriate fillers in dynamic areas leading to mechanical aggregation of the filler (for example, the use of particulate fillers near the lip or placement of PLLA in concentric muscles). 2 This type of nodule generally presents a few weeks postprocedure, becomes hard, and is locally confined. Noninflammatory early onset nodules remain the same size until absorbed, treated, or removed.
Treatment of noninflammatory early onset nodules depends on the filler used. Nodules due to HA fillers can be resolved with hyaluronidase followed by nicking and extruding the product. Early developing PLLA fillers may respond to a crack, massage, and saline injection protocol. Early onset nodules with CaHA may respond to sterile water injection.
Early Onset Inflammatory Nodules (Infection-Related Nodules)
Though infection-related nodules most often present within two weeks postprocedure, they can present later as biofilm-associated nodules. Infection-related nodules are often localized and do not generally present in a symmetrical fashion. Nodules that result from infection should be treated with drainage and/or antibiotics when indicated (if wounds appear red or inflamed), and patients should avoid non-steroidal anti-inflammatory drugs (NSAIDs) or steroids, as these agents may worsen infection. Proper incision and drainage of pus is critically important, as failure to properly drain the wound may lead to permanent indentation at the site of the infection. A small incision with careful probing to break apart pus locations and insertion of a tiny drain overnight may obviate the need for antibiotics and ensure complete resolution of the infection.
Late-Onset Inflammatory Nodules
Because "granuloma" is a pathologic diagnosis, late-onset inflammatory nodules, whether infectious or noninfectious, are most often diagnosed clinically. For this reason, the authors propose that "granulomas" be referred to as late-onset inflammatory nodules.
Noninfectious, Late-Onset, Noninflammatory Nodules
Late-onset noninflammatory nodules are most common PLLA and particulate fillers. These nodules result from product accumulation and do not have the hallmarks of inflammation. One common example is PLLA nodules in the hand. A first-line attempt at resolution is mechanical disruption with a needle; however, this type of nodule is difficult to treat, and excision is often required.
Noninfectious, Late-Onset Inflammatory Nodules (Granuloma)
These nodules typically present at all implantation sites simultaneously, many months to years after injection in all areas injected with filler. The symmetry of these nodules is an important clinical differentiator from infectious nodules and reflects the systemic response, rather than the localized response of infection. Unlike later-onset infectious nodules, which are relatively rare, late-onset inflammatory nodules are likely due to a cellular hypersensitivity response with continuous foreign body reaction. Nodules are often erythematous, edematous, tense, and sometimes purplish, due to congested capillaries.
Though a direct cause of noninfectious, late-onset inflammatory nodules is unknown, systemic inflammatory events such as influenza have been observed clinically as potential triggers. Systemic infection, virus, trauma, or operation may act as a stimulus, causing reactivation of macrophages to induce a sudden foreign-body reaction. Late-onset inflammatory nodules (granulomas) may exhibit temporary flare ups and regressions: without treatment, these late-onset noninflammatory nodules may grow, persist, and then spontaneously resolve within 1 to 5 years after onset.
Overall, noninfectious, late-onset inflammatory nodules seldom have defined borders, making excision difficult. Late-onset PLLA, PMMA, or CaHA nodules may respond to an injectable steroid (triamcinolone)/5-FU combination (50/50 mixture) which can be mixed with lidocaine. This can be repeated at 3 to 4 week intervals and monitored by response. If no progression is observed, excision, laser melting, treatment with collagenase, external heat administration, and in some cases laser excision may be used. The treatment algorithm for late-onset, noninfectious inflammatory nodules is shown in Figure 1 .
Histologic Variability Among Noninfectious Late-Onset Inflammatory Nodules
Though the incidence of noninfectious late-onset inflammatory nodules is not restricted to any single type of filler, different "types" of foreign body granulomas (FBGs) that give rise to these nodules are more common with particular fillers. While pathologic substratum differs, histologic reaction is invariably similar: The presence of macrophages defines foreign body granulomas, which often fuse to form multinucleated giant cells. These macrophages have elongated, larger nuclei, differentiating them from normal macrophages, and are typically tightly clustered, obscuring the borders of the cells.
FBGs include cystic granulomas, edematous granulomas, and sclerosing granulomas. Cystic granulomas occur mainly with biologic gels such as hyaluronic acid gels and collagens. Their appearance is often red, indurated, or fluctuant. Edematous granulomas, sometimes referred to as "lipogranulomas," are usually associated with artificial fluids such as silicone oil and polyacrylamides, but can also be associated with particulate, stimulatory fillers. A late-onset edematous FBG resulting from a PMMA injection (Artefill) is shown in Figure 2A , along with resolution after treatment ( Figure 2B and C) . Sclerosing granulomas are usually associated with the particulate stimulatory fillers PMMA, CaHA, and PLLA. These longer lasting, particulate implants do not have a comparatively higher rate of FBGs when compared that of HAs; however, clinical appearance is more pronounced and these FBGs may persist longer if left untreated.
Infectious Late-Onset Inflammatory Nodules
Biofilm-associated infected nodules are a type of late-onset inflammatory nodules. Biofilms may develop on fluid filler material injected into the skin or subcutaneous tissue. Biofilms are groups of microorganisms that attach to living wounds or inert surfaces where they produce a protective matrix (biofilm). Biofilms form on other implantable substances, such as breast implants (capsules) and in-dwelling catheters. They may give rise to a low-grade, chronic, antibiotic-resistant infection, and may be reactivated by trauma from additional dermal filler procedures.
Cleansing the face prior to the injection using a providone-iodine, chlorhexidine, or benzalkonium chloride preparation is the most effective way to prevent biofilms. Further, minimizing the number of injection puncture sites and avoiding bolus injections also minimize risk. Intraoral injection should be avoided if possible. Injections should be postponed if an infection is present, and prophylactic antibiotics should be given if the patient has a dental procedure or facial infection within two weeks of the treatment.
Standard culturing techniques often fail to identify biofilms, necessitating molecular studies to confirm the presence of the biofilm and identify resident organisms. Techniques in identifying biofilm organisms such as realtime polymerase chain reaction, pyrosequencing, fluorescent in situ hybridization, and ultrasound sonification may be utilized. Broad-spectrum antibiotic treatment usually with quinolones and macrolides is the first step in treating a patient with a suspected biofilm. It is imperative to attempt to identify and differentiate between biofilm-related infectious etiology nodules vs inflammatory foreign body granulomas as the treatments differ. If biofilm infection is only suggested, culture is negative, and the presentation is more indicative of FBG, antibiotics can delay effective treatment of the granuloma with intralesional steroids for months. 32 Though molecular techniques may permit treatment with focused antibiotic therapy, reducing contributions to resistance, the complex, multispecies composition of the biofilm may necessitate use of broad-spectrum antibiotics. If the presence of bacteria is confirmed or presentation is more consistent with infection, treatment, as outlined in Figure 3 , should exclude use of steroids or NSAIDs. The patient should be given an injection of a hyaluronidase 15 to 30 U mixed 1:1 with saline. In addition, antibiotic treatment of oral quinolone/macrolides (Cipro [Bayer Corporation, Pittsburgh, PA] 500 mg + Biaxin [Abbot Laboratories, Chicago, IL] 500 mg BID) should be prescribed for up to 6 weeks. If the infection persists, the patient can be given intravenous or intramuscular antibiotics (eg, vancomycin, lincomycin, or teicoplanin), every other day for 10 days, followed by oral antibiotics for 10 days. If fluctuant, incision and drainage should be performed and the exudate cultured. The incised abscess should be washed out with antibiotics after cultures are taken.
As standard culture and sensitivity testing often yields no identifiable organisms, the terminology "sterile abscess" has often been erroneously applied to infectious nodules. For these "sterile abscesses," the culprit is likely a variety of biofilm-stimulating organisms. Though a biofilm can consist of a single bacterial or fungal species, biofilms are usually polymicrobial. 33 Further, the causative microorganisms only comprise 10% to 20% of the biofilm, with the remaining portion composed of a secreted extracellular polymeric substance (EPS). 34 The EPS makes penetration and therefore treatment of the biofilm infections difficult. Aspiration or drainage should be repeated as necessary if there is fluctuance noted. Washing the area out with a high osmolarity surfactant is emerging as an additional step in treating the biofilm and dispersing the EPS. 35 Figure 4 shows drainage of an infectious nodule with a suspected biofilm.
Any remaining nodules that are firm and no longer fluctuant should be treated with intra-lesional triamcinolone/5-FU (50 mg/cc) in a 50/50 mix of volume plus an additional 0.1 cc of 1% lidocaine mixture repeated every 3 to 4 weeks. Additionally, external heat such as radiofrequency or ultrasound may help disrupt the EPS and thereby promote nodule dissolution. If combination intralesional triamcinolone and antibiotic therapy fail to resolve a remaining firm biofilm-associated nodule, the nodule should be treated with laser-assisted liquefaction. Improvement after laser fiber melting (980 nm) of an inflammatory nodule on the back of the leg is shown in Figure 5 . If the nodules persist, excision can be used as a last resort.
Vascular Occlusion/Tissue Compromise
There is the potential for serious vascular events with any type of filler. Causative mechanisms include accidental injection into an artery, compression due to excessive pressure on an artery from injection, and high-volume injections that are given too quickly or deeply. The resulting ischemia can be painful and infarction may result in tissue hypoxia, tissue death, and necrosis. 36 Effective treatment of vascular complications begins with sufficient prevention: this aspect of patient care is so critical that primary prevention strategies are mentioned here as well. The authors emphasize that though the incidence of adverse events with fillers is low, it is the ethical responsibility of the injector to not only be aware of the appropriate treatment, but to be prepared to administer it immediately. Injecting physicians should have hyaluronidase immediately available as well as a range of supplemental treatment options such as nitro paste, warm compresses, aspirin, sildenafil, and an ophthalmologist's phone number readily available. Early recognition and rapid response provides the greatest potential to impact patient outcomes in the event of vascular occlusion. Access to hyperbaric oxygen therapy may be another useful option. Further, it is the responsibility of the physician to educate their office staff about the signs of occlusion should patients contact the office postinjection. It is rare for patients to call the office postinjection, so any complaints of bruising, mottling, numbness, or pain should be taken seriously.
Vascular compromise may be split into those that result in visual problems and occlusion of the soft-tissue vasculature, as they are handled differently. The treatment algorithms outlined below may be explored in greater depth by examining consensus treatment recommendations. 37 
Soft Tissue
Blanching may occur during or shortly after an injection, however it is rare that there are absolutely no signs of vascular occlusion or compression at the time of injection. 38 A recent publication by Claudio DeLorenzi, MD serves as an excellent guide for treatment of HA filler vascular adverse events, and provides a hyaluronidase dosing protocol based on the surface area of ischemic tissue. 38 This article provides a comprehensive update and provides treatment algorithms based on the principal of hyaluronidase flooding, so the authors of this manuscript will not rehash the treatment algorithm here, but recommend a thorough reading of the manuscript. To reinforce the importance of rapid response to vascular compromise, Figure 6 shows results from immediate treatment of vascular compromise by injection of hyaluronidase.
One aspect of care that remains to be detailed is how to best handle soft-tissue compromise when it results from treatment with non-HA fillers, as well as how to best treat filler complications after 48 hours (Figure 7 ). For treating vascular compromise from injection with PLLA, PMMA or CaHA, emergency measures include complete cessation of injection and massage to aid in dispersion of the product if compression, rather than occlusion, is suspected. The patient should be given between 400 and 600 units of undiluted hyaluronidase per area affected, administered directly into the area where the filler has been injected. Collagenase may also be used, if available. Initial injection is followed by observation and subsequent retreatment in an hour, if necessary. It is impossible to predict the amount of hyaluronidase that will be needed to resolve the occlusion, as this is often highly patient specific. In discussing the use of hyaluronidase for treatment of vascular complications with non-HA fillers, the authors agree that hyaluronidase should still be used immediately upon threatened vascular compromise, as it may degrade the carrier gel, or the surrounding soft tissue turgor to some degree, and promote dispersion. While hyaluronidase is not specifically designed to degrade non-HA fillers, hyaluronidase or collagenase are the most likely agents to aid in dispersal. Though nitro paste and hyperbaric oxygen are not effective ancillary therapy for HA fillers in early management of vascular compromise, they remain an important aspect of treatment for particulate filler vascular compromise, as all measures should be undertaken to reverse compromise. Further, these therapies are of central importance in wound care, especially for treatment of soft tissue sequelae. Effective wound care and management is critical in the time after 48 hours, or once the skin is in the livedo phase and has begun to blister (approximately 4 days postinjection), or is in the beginning stages of necrosis (1-week postinjection). Due to the severity of the consequences of unresolved vascular compromise, the authors do recommend these measures for CaHA, PLLA, and PMMA. In the absence of confirmed infection, antibiotics should not be used. Importantly, a recent case study illustrated the utility of aggressive platelet-rich plasma (PRP). 39 Controversy in the medical community persists over the existence of compression as a real clinical entity. Though animal model studies support intraluminal injection as a mechanism for vascular compromise, the existence of proximal tissue compromise in the presence of distal injection and the occurrence of tissues compromise in watershed areas where skin is densely bound support compression as a mechanism. 40, 41 Since the presentation of compression and occlusion are indistinguishable clinically, any restriction in blood flow should be treated the same. Because hyaluronidase is known to penetrate blood vessels, 42 it should be used aggressively regardless of the suspected nature of the blood flow restriction. Any aspirin administered should be ground and put under the patient's tongue to speed absorption.
The hyaluronidase preparations commonly discussed in international publications do not relate to the products available in the United States, making the doses listed of no use. Also, the expanding range of HA fillers entering the US market respond differently to hyaluronidase due to differences in degree and types of cross-linking. Both of the commonly available hyaluronidase preparations in the United States, Vitrase and Hylenex (Halozyme Therapeutics, San Diego, CA), seem to have a similar effect in degrading the traditionally available HA fillers. 36 The most important difference is that Hylenex is recombinant, lacking ovine proteins present in Vitrase that may cause allergic reactions.
Ocular
Occlusion of the ophthalmic artery after filler procedures is a risk, and can also result from filler occlusion or compression of the ophthalmic, central retinal, or branch retinal artery. Occlusion following injection into distant sites, most commonly the glabella, nasal region, nasolabial fold, and forehead. 43 The prognosis for patients with this complication is poor, and the most common outcome is irreversible vision loss. 44 Classical treatment considerations include ocular massage, anterior chamber paracentesis, acetazolamide, intravenous corticosteroids (topical will not increase blood flow or reach necrosis), carbogen inhalation, hyperbaric oxygen, intra-arterial fibrinolysis, aspirin, enoxaparin sodium, and heparin. The authors wish to emphasize the importance of treating this type of complication immediately. Circulation must be restored within 60 to 90 minutes or the damage is irreversible. While an ophthalmologist should be consulted immediately, this is often not possible within this very short time window. Due to the urgency of the situation, a retrobulbar or peribulbar injection with hyaluronidase must be given, though with tempered expectations. The injection may be given with an Atkinson needle or cannula. Though there is an incidence of bleeding following retrobulbar injection, the threat to the patient's vision eclipses this concern. The peribulbar injection that tracks along the floor of the orbit has less risk of bleeding and perforation of the globe. While this approach delivers hyaluronidase outside the muscular conus containing the central retinal artery, the medicine will likely diffuse into the required area. As with soft tissue occlusion, dosing should be repeated if no response is obtained.
Though an ophthalmologist should be consulted as soon as possible, the only meaningful opportunity to affect a reversal of the occlusion is nearly always in the hands of the injector or supervising MD. Familiarity with these important rescue techniques, though they may be well outside of the "comfort zone" of many practitioners, might partially avert the sequelae of this devastating event.
DISCUSSION
As the number and type of fillers continues to expand, so must understanding of how to best prevent and treat complications. Though prevention is certainly best, knowledge of the most efficient and efficacious modes of treatment for complications is an ethical responsibility of an injector. The authors wish to emphasize that it is the obligation of an injector to keep hyaluronidase on hand, as early intervention with this agent may reverse otherwise significant damage.
In order to successfully treat nodules, it is important that they be properly diagnosed as inflammatory, noninflammatory, or infectious. Careful consideration of the clinical presentation of the different types of nodules can effectively guide treatment and ensure proper management. The treatment algorithms outlined here provide the injector of treatment approach for several types of complications.
CONCLUSION
Dermal fillers are considered by many to be an efficient way to quickly enhance facial aesthetics with minimal downtime. Physicians must consider the individual characteristics of each patient and available filler when making treatment selections. While adverse events are rare, serious complications can result. Both preparation on the part of the physician to handle rare adverse events and the ability to accurately identify the complication's etiology ensures optimal treatment. If a nodule, granuloma, or vascular occlusion or tissue compromise has occurred, following the treatment algorithms described in this paper will help mitigate treatment insult. Suitable product selection, appropriate procedure, and skillful injection technique are paramount on the part of the practitioner to avoid most adverse events.
